Resibufogenin inhibits the malignant characteristics of multiple myeloma cells by blocking the PI3K/Akt signaling pathway

Resibufogenin (RBG) is an active ingredient of toad venom that also has antitumor potential. The present study aimed to investigate the role of RBG in multiple myeloma (MM) and the underlying action mechanism involving the PI3K/Akt signaling pathway. A human MM cell line, RPMI8226, was treated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yan, Hong, Zirui, Jin, Keting, Lin, Chenjun, Xiang, Jingjing, Ge, Hangping, Zheng, Zhiyin, Shen, Jianping, Deng, Shu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185807/
https://www.ncbi.nlm.nih.gov/pubmed/35720619
http://dx.doi.org/10.3892/etm.2022.11368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185807/
https://www.ncbi.nlm.nih.gov/pubmed/35720619
http://dx.doi.org/10.3892/etm.2022.11368

Ejemplares similares